Using principal component analysis for the prediction of tumor response to transarterial chemoembolization.

Purpose: To quantitate the tumor blush of hepatocellular carcinoma (HCC) at the time of transarterial chemoembolization (TACE) using principal component analysis (PCA), and to correlate the quantitated tumor blush to response to therapy. Materials and methods: In this proof-of-concept study, 27 prim...

Descripción completa

Detalles Bibliográficos
Publicado en:Abdominal Radiology Vol. 44; no. 7; pp. 2594 - 2602
Autores principales: Miller, Jessica P., Ramaswamy, Raja, Akinwande, Olaguoke
Formato: Journal Article
Publicado: Springer Nature Jul2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=136915269&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 136915269
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        2366004X
        JT14
      jtl: Abdominal Radiology
      issn: 2366004X
      maglogo: N
    pubinfo:
      dt: Jul2019
      vid: 44
      iid: 7
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        136915269
        10.1007/s00261-019-01982-9
        136915269
      ppf: 2594
      ppct: 8
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Using principal component analysis for the prediction of tumor response to transarterial chemoembolization.
      aug:
        au:
          Miller, Jessica P.
          Ramaswamy, Raja
          Akinwande, Olaguoke
        affil: Washington University School of Medicine, 660 S. Euclid Ave., 63110, St. Louis, MO, USA
      sug:
      ab: Purpose: To quantitate the tumor blush of hepatocellular carcinoma (HCC) at the time of transarterial chemoembolization (TACE) using principal component analysis (PCA), and to correlate the quantitated tumor blush to response to therapy. Materials and methods: In this proof-of-concept study, 27 primary HCC tumors in 25 patients (18 men, 7 women; mean age 66 years ± 9) were analyzed. We conducted a retrospective analysis of TACE procedures that were performed during March through July of 2017. Digital subtraction angiography (DSA) was combined with PCA to condense spatial and temporal information into a single image. The tumor and liver contrast enhancements were calculated, and the ratio was used to determine the relative vascular enhancement of the tumor. Tumor response to therapy was determined at 1-month post procedure. Results: Using PCA-generated fluoroscopic imaging (PCA-FI), we quantitated the tumor blush and assigned a vascular enhancement value (VEV) to each tumor. Tumors that responded to treatment (N = 12) had statistically higher VEVs compared with the nonresponders (N = 15), with a mean value of 0.96 ± 0.455 vs. 0.57 ± 0.309, (p = 0.013). Conclusions: We developed a method for quantitating tumor blush using routine angiographic images. The VEVs calculated using these images may allow for the prediction of tumor response to therapy. This pilot study suggests that there is a correlation between tumor blush intensity and tumor response.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N